Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.
Study Details
Study Description
Brief Summary
In a randomized controlled design with approximately 26 biweekly sessions over 12 months, the investigators propose to test the effectiveness of an ECHO-based intervention for improving the use of clozapine in people eligible for clozapine. The sessions will include: 1) active dissemination of knowledge and information by an expert "hub" followed by 2) clozapine case presentations and vignettes submitted by the "spokes".
This intervention, Clozapine CHAMPION-ECHO (Center for Help and Assistance for Maryland Prescribers- Improving Outcomes Network using Extension for Community Healthcare Outcomes, will be referred to as "CHAMPION" throughout.. To minimize ANC monitoring barriers and maximize recruitment, the investigators will provide Food and Drug Administration (FDA)-cleared ANC point of care (POC) monitoring devices to all study sites, including those in the control condition. The investigators will enroll at least 300 prescribers and additional clinical team members (up to 300) from 60 outpatient mental health clinics (OMHCs) and other treatment sites; approximately half the OHMCs will be randomized to CHAMPION and half randomized to enhanced treatment as usual (ETAU).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Education sessions Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes. |
Other: Education Sessions
Project ECHO (Extension for Community Healthcare Outcomes) based intervention sessions for improving the use of clozapine in people with treatment-resistant schizophrenia. The sessions will include: 1) active dissemination of knowledge and information by an expert followed by 2) clozapine case presentations and vignettes.
|
| Placebo Comparator: No education sessions
|
Other: No Education Session
No Education Session
|
Outcome Measures
Primary Outcome Measures
- change in clozapine prescriptions using Medicaid claims data [Baseline and endpoint changes after 12 month intervention]
The data outcome is new clozapine prescriptions by provider based on a variable linking provider ID to clozapine prescriptions. The outcome is the increase in the proportion of patients treated with clozapine for those in the care of prescribers randomized to the CHAMPION relative to the ETAU condition.
- Change in prescriber knowledge of clozapine use [Baseline and endpoint changes after 12 month intervention]
A 52 item Multiple Choice Questionnaire will be used to assess knowledge. The knowledge-based test questions will consist of 2 questions per 26 topic areas and will conform to best practices and guidelines for design of the questions. The total mean score will range from 0-52. The questions were developed and validated by the team.
- Change in self-reported competence for clozapine use [Baseline and endpoint changes after 12 month intervention]
We will use a mean score on a Visual Analog Scale (VAS) (0-100 mm). We will have one for overall competence and then one for each of the 26 topic areas. Overall, self report scores and the global self report scores will be used.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Located at a site in the State of Maryland with at least 3 prescribers at the site.
-
Prescribers/clinical team should be licensed in the State of Maryland and have prescribed antipsychotics previously.
-
Between the ages of 22 and 85 years old
-
Willing to participate in pre- and post-testing
-
Willing to agree to try to participate in the CHAMPION sessions
Exclusion Criteria:
- Not willing to participate in CHAMPION Sessions
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP) | Catonsville | Maryland | United States | 21228 |
Sponsors and Collaborators
- University of Maryland, Baltimore
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HP-00087339